{"id":745664,"date":"2018-09-20T15:30:00","date_gmt":"2018-09-20T15:30:00","guid":{"rendered":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/"},"modified":"2025-11-07T01:27:02","modified_gmt":"2025-11-07T06:27:02","slug":"merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in","status":"publish","type":"news_item","link":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/","title":{"rendered":"Merck Receives Positive CHMP Opinion for DELSTRIGO\u2122 (doravirine\/lamivudine\/tenofovir disoproxil fumarate) and PIFELTRO\u2122 (doravirine) in the European Union for the Treatment of HIV-1 Infection"},"content":{"rendered":"<p>KENILWORTH, N.J.&#8211;(<a target=\"_blank\" href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;Merck (NYSE: MRK), known as MSD outside the United States and Canada,<br \/>\n      today announced that the Committee for Medicinal Products for Human Use<br \/>\n      (CHMP) of the European Medicines Agency (EMA) has adopted a positive<br \/>\n      opinion recommending granting of marketing authorization for two HIV-1<br \/>\n      medicines: DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of<br \/>\n      doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil<br \/>\n      fumarate (TDF, 300 mg); and PIFELTRO\u2122 (doravirine, 100 mg), a new<br \/>\n      non-nucleoside reverse transcriptase inhibitor (NNRTI) to be<br \/>\n      administered in combination with other antiretroviral medicines.<br \/>\n      DELSTRIGO and PIFELTRO are currently under EMA review for the treatment<br \/>\n      of adults with HIV-1 infection without past or present evidence of<br \/>\n      resistance to the non-nucleoside reverse transcriptase class, lamivudine<br \/>\n      or tenofovir. These two recommendations will now be reviewed by the<br \/>\n      European Commission for marketing authorization in the European Union.<br \/>\n      Marketing authorization applications for DELSTRIGO and PIFELTRO are also<br \/>\n      under review in other countries, including Canada, Australia, and<br \/>\n      Switzerland.\n    <\/p>\n<p>\n      \u201cWe are pleased with the CHMP\u2019s positive opinion recommending approval<br \/>\n      of DELSTRIGO and PIFELTRO, which marks an important step forward in<br \/>\n      advancing new treatments for people living with HIV,\u201d said Dr. George<br \/>\n      Hanna, vice president and therapeutic area head of infectious diseases,<br \/>\n      Global Clinical Development, Merck Research Laboratories. \u201cThis<br \/>\n      represents another milestone in Merck\u2019s more than 30-year commitment to<br \/>\n      HIV research and treatment, and advances our efforts to address the<br \/>\n      unmet needs of the HIV community worldwide.\u201d\n    <\/p>\n<p>\n      The CHMP positive opinion was based on findings from two pivotal,<br \/>\n      randomized, multicenter, double-blind, active controlled Phase 3 trials,<br \/>\n      DRIVE-AHEAD and DRIVE-FORWARD, evaluating the efficacy and safety of<br \/>\n      DELSTRIGO and PIFELTRO, respectively, in participants infected with<br \/>\n      HIV-1 with no prior antiretroviral treatment history. In DRIVE-AHEAD,<br \/>\n      DELSTRIGO demonstrated sustained viral suppression through 48 weeks,<br \/>\n      meeting its primary endpoint of non-inferior efficacy compared to<br \/>\n      efavirenz (EFV)\/emtricitabine (FTC)\/TDF. In DRIVE-FORWARD, PIFELTRO<br \/>\n      demonstrated sustained viral suppression through 48 weeks, meeting its<br \/>\n      primary endpoint of non-inferior efficacy compared to darunavir +<br \/>\n      ritonavir, each in combination with FTC\/TDF or abacavir (ABC)\/3TC.\n    <\/p>\n<p>\n      The U.S. Food and Drug Administration approved DELSTRIGO and PIFELTRO on<br \/>\n      August 30, 2018. In the United States, both DELSTRIGO and PIFELTRO are<br \/>\n      indicated for the treatment of HIV-1 infection in adult patients with no<br \/>\n      prior antiretroviral treatment experience, and are administered orally<br \/>\n      once daily with or without food. DELSTRIGO contains a boxed warning<br \/>\n      regarding post-treatment acute exacerbations of hepatitis B (HBV)<br \/>\n      infection. DELSTRIGO and PIFELTRO do not cure HIV-1 infection or AIDS.\n    <\/p>\n<p>\n      <b>Selected Safety Information about DELSTRIGO (doravirine\/3TC\/TDF) in<br \/>\n      the U.S.<\/b>\n    <\/p>\n<p>\n      <i>Warning: Post treatment Acute Exacerbation of Hepatitis B (HBV)<\/i>\n    <\/p>\n<p>\n      All patients with HIV-1 should be tested for the presence of HBV before<br \/>\n      initiating antiretroviral therapy. Severe acute exacerbations of HBV<br \/>\n      have been reported in patients who are coinfected with HIV-1 and HBV and<br \/>\n      have discontinued products containing lamivudine or TDF, which are<br \/>\n      components of DELSTRIGO. Patients coinfected with HIV-1 and HBV who<br \/>\n      discontinue DELSTRIGO should be monitored with both clinical and<br \/>\n      laboratory follow-up for at least several months after stopping<br \/>\n      DELSTRIGO. If appropriate, initiation of anti-HBV therapy may be<br \/>\n      warranted.\n    <\/p>\n<p>\n      DELSTRIGO is contraindicated when co-administered with drugs that are<br \/>\n      strong cytochrome P450 (CYP)3A enzyme inducers (including the<br \/>\n      anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and<br \/>\n      phenytoin; the androgen receptor inhibitor enzalutamide; the<br \/>\n      antimycobacterials rifampin and rifapentine; the cytotoxic agent<br \/>\n      mitotane; and the herbal product St. John\u2019s wort (Hypericum<br \/>\n      perforatum)), as significant decreases in doravirine plasma<br \/>\n      concentrations may occur, which may decrease the effectiveness of<br \/>\n      DELSTRIGO. DELSTRIGO is contraindicated in patients with a previous<br \/>\n      hypersensitivity reaction to lamivudine.\n    <\/p>\n<p>\n      Renal impairment, including cases of acute renal failure and Fanconi<br \/>\n      syndrome, have been reported with the use of TDF. DELSTRIGO should be<br \/>\n      avoided with concurrent or recent use of a nephrotoxic agent, as cases<br \/>\n      of acute renal failure after initiation of high-dose or multiple NSAIDs<br \/>\n      have been reported in patients with risk factors for renal dysfunction<br \/>\n      who appeared stable on TDF.\n    <\/p>\n<p>\n      Prior to or when initiating DELSTRIGO, and during treatment, assess<br \/>\n      serum creatinine, estimated creatinine clearance, urine glucose and<br \/>\n      urine protein in all patients. In patients with chronic kidney disease,<br \/>\n      also assess serum phosphorus. Discontinue DELSTRIGO in patients who<br \/>\n      develop clinically significant decreases in renal function or evidence<br \/>\n      of Fanconi syndrome. Discontinue DELSTRIGO if estimated creatinine<br \/>\n      clearance declines below 50 mL\/min.\n    <\/p>\n<p>\n      In clinical trials in HIV-1 infected adults, TDF was associated with<br \/>\n      slightly greater decreases in bone mineral density (BMD) and increases<br \/>\n      in biochemical markers of bone metabolism. Serum parathyroid hormone<br \/>\n      levels and 1,25 vitamin D levels were also higher. Cases of osteomalacia<br \/>\n      associated with proximal renal tubulopathy have been reported with the<br \/>\n      use of TDF.\n    <\/p>\n<p>\n      Immune reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment. Because DELSTRIGO is a complete<br \/>\n      regimen, co-administration with other antiretroviral medications for the<br \/>\n      treatment of HIV-1 infection is not recommended.\n    <\/p>\n<p>\n      Consult the full Prescribing Information prior to and during treatment<br \/>\n      for important potential drug-drug interactions.\n    <\/p>\n<p>\n      If co-administered with rifabutin, take one tablet of DELSTRIGO once<br \/>\n      daily, followed by one tablet of doravirine (PIFELTRO) approximately 12<br \/>\n      hours after the dose of DELSTRIGO. The most common adverse reactions<br \/>\n      with DELSTRIGO (incidence \u22655%, all intensities) were dizziness (7%),<br \/>\n      nausea (5%) and abnormal dreams (5%).\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in individuals exposed to DELSTRIGO during pregnancy. Healthcare<br \/>\n      providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry at 1-800-258-4263. Mothers infected<br \/>\n      with HIV-1 should be instructed not to breastfeed if they are receiving<br \/>\n      DELSTRIGO due to the potential for HIV-1 transmission. Because DELSTRIGO<br \/>\n      is a fixed-dose combination tablet and the components cannot be altered,<br \/>\n      it is not recommended in patients with estimated creatinine clearance<br \/>\n      less than 50 mL\/min.\n    <\/p>\n<p>\n      <b>Selected Safety Information about PIFELTRO (doravirine) in the U.S.<\/b>\n    <\/p>\n<p>\n      PIFELTRO is contraindicated when co-administered with drugs that are<br \/>\n      strong cytochrome P450 (CYP)3A enzyme inducers (including the<br \/>\n      anticonvulsants carbamazepine, oxcarbazepine, phenobarbital, and<br \/>\n      phenytoin; the androgen receptor inhibitor enzalutamide; the<br \/>\n      antimycobacterials rifampin and rifapentine; the cytotoxic agent<br \/>\n      mitotane; and the herbal product St. John\u2019s wort (Hypericum<br \/>\n      perforatum)), as significant decreases in PIFELTRO plasma concentrations<br \/>\n      may occur, which may decrease the effectiveness of PIFELTRO. Immune<br \/>\n      reconstitution syndrome can occur, including the occurrence of<br \/>\n      autoimmune disorders with variable time to onset, which may necessitate<br \/>\n      further evaluation and treatment. Co-administration of PIFELTRO with<br \/>\n      efavirenz, etravirine or nevirapine is not recommended. If<br \/>\n      co-administered with rifabutin, increase PIFELTRO dosage to one tablet<br \/>\n      twice daily (approximately 12 hours apart).\n    <\/p>\n<p>\n      Consult the full Prescribing Information prior to and during treatment<br \/>\n      for important potential drug-drug interactions. The safety of PIFELTRO<br \/>\n      is based on two studies, DRIVE-FORWARD and DRIVE-AHEAD. In<br \/>\n      DRIVE-FORWARD, the most common adverse reactions (incidence \u22655%, all<br \/>\n      intensities) were nausea (7%), headache (6%), fatigue (6%), diarrhea<br \/>\n      (5%) and abdominal pain (5%). In DRIVE-AHEAD, the most common adverse<br \/>\n      reactions (incidence \u22655%, all intensities) were dizziness (7%), abnormal<br \/>\n      dreams (5%) and nausea (5%).\n    <\/p>\n<p>\n      There is a pregnancy exposure registry that monitors pregnancy outcomes<br \/>\n      in individuals exposed to PIFELTRO during pregnancy. Healthcare<br \/>\n      providers are encouraged to register patients by calling the<br \/>\n      Antiretroviral Pregnancy Registry at 1-800-258-4263. Mothers infected<br \/>\n      with HIV-1 should be instructed not to breastfeed if they are receiving<br \/>\n      PIFELTRO due to the potential for HIV transmission.\n    <\/p>\n<p>\n      <b>About Merck<\/b>\n    <\/p>\n<p>\n      For more than a century, Merck, a leading global biopharmaceutical<br \/>\n      company known as MSD outside of the United States and Canada, has been<br \/>\n      inventing for life, bringing forward medicines and vaccines for many of<br \/>\n      the world&#8217;s most challenging diseases. Through our prescription<br \/>\n      medicines, vaccines, biologic therapies and animal health products, we<br \/>\n      work with customers and operate in more than 140 countries to deliver<br \/>\n      innovative health solutions. We also demonstrate our commitment to<br \/>\n      increasing access to health care through far-reaching policies, programs<br \/>\n      and partnerships. Today, Merck continues to be at the forefront of<br \/>\n      research to advance the prevention and treatment of diseases that<br \/>\n      threaten people and communities around the world &#8211; including cancer,<br \/>\n      cardio-metabolic diseases, emerging animal diseases, Alzheimer&#8217;s disease<br \/>\n      and infectious diseases including HIV and Ebola. For more information,<br \/>\n      visit <a href=\"http:\/\/vip2-msd.com\/merckcom-migrated\" rel=\"nofollow\">vip2-msd.com\/merckcom-migrated<\/a><br \/>\n      and connect with us on <a href=\"https:\/\/twitter.com\/Merck\" rel=\"nofollow\">Twitter<\/a>,<br \/>\n      <a href=\"https:\/\/www.facebook.com\/MerckInvents\/\" rel=\"nofollow\">Facebook<\/a>,<br \/>\n      <a href=\"https:\/\/www.instagram.com\/merck\/\" rel=\"nofollow\">Instagram<\/a>,<br \/>\n      <a href=\"https:\/\/www.youtube.com\/user\/Merck\" rel=\"nofollow\">YouTube<\/a><br \/>\n      and <a href=\"https:\/\/www.linkedin.com\/company\/merck\/\" rel=\"nofollow\">LinkedIn<\/a>.\n    <\/p>\n<p>\n      <b>Forward-Looking Statement of Merck &amp; Co., Inc., Kenilworth, N.J., USA<\/b>\n    <\/p>\n<p>\n      This news release of Merck &amp; Co., Inc., Kenilworth, N.J., USA (the<br \/>\n      \u201ccompany\u201d) includes \u201cforward-looking statements\u201d within the meaning of<br \/>\n      the safe harbor provisions of the U.S. Private Securities Litigation<br \/>\n      Reform Act of 1995. These statements are based upon the current beliefs<br \/>\n      and expectations of the company\u2019s management and are subject to<br \/>\n      significant risks and uncertainties. There can be no guarantees with<br \/>\n      respect to pipeline products that the products will receive the<br \/>\n      necessary regulatory approvals or that they will prove to be<br \/>\n      commercially successful. If underlying assumptions prove inaccurate or<br \/>\n      risks or uncertainties materialize, actual results may differ materially<br \/>\n      from those set forth in the forward-looking statements.\n    <\/p>\n<p>\n      Risks and uncertainties include but are not limited to, general industry<br \/>\n      conditions and competition; general economic factors, including interest<br \/>\n      rate and currency exchange rate fluctuations; the impact of<br \/>\n      pharmaceutical industry regulation and health care legislation in the<br \/>\n      United States and internationally; global trends toward health care cost<br \/>\n      containment; technological advances, new products and patents attained<br \/>\n      by competitors; challenges inherent in new product development,<br \/>\n      including obtaining regulatory approval; the company\u2019s ability to<br \/>\n      accurately predict future market conditions; manufacturing difficulties<br \/>\n      or delays; financial instability of international economies and<br \/>\n      sovereign risk; dependence on the effectiveness of the company\u2019s patents<br \/>\n      and other protections for innovative products; and the exposure to<br \/>\n      litigation, including patent litigation, and\/or regulatory actions.\n    <\/p>\n<p>\n      The company undertakes no obligation to publicly update any<br \/>\n      forward-looking statement, whether as a result of new information,<br \/>\n      future events or otherwise. Additional factors that could cause results<br \/>\n      to differ materially from those described in the forward-looking<br \/>\n      statements can be found in the company\u2019s 2017 Annual Report on Form 10-K<br \/>\n      and the company\u2019s other filings with the Securities and Exchange<br \/>\n      Commission (SEC) available at the SEC\u2019s Internet site (<a href=\"https:\/\/www.sec.gov\/\" rel=\"nofollow\">www.sec.gov<\/a>).\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for DELSTRIGO (doravirine\/3TC\/TDF)<br \/>\n      at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>;<\/b>\n    <\/p>\n<p>\n      <b>Patient Information for DELSTRIGO (doravirine\/3TC\/TDF) at <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/d\/delstrigo\/delstrigo_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<p>\n      <b>Please see Prescribing Information for PIFELTRO (doravirine) at: <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_pi.pdf<\/b><br \/>\n<\/a><br \/>\n<b>;<\/b>\n    <\/p>\n<p>\n      <b>Patient Information for PIFELTRO (doravirine) at <\/b><br \/>\n<a href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_ppi.pdf\" rel=\"nofollow\"><br \/>\n<b>https:\/\/vip2-msd.com\/merckcom-migrated\/product\/usa\/pi_circulars\/p\/pifeltro\/pifeltro_ppi.pdf<\/b><br \/>\n<\/a>\n    <\/p>\n<\/p>\n<p>\n<img decoding=\"async\" alt=\"\" src=\"\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20180920005748r1&amp;sid=hq1sc1&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><br \/>\n<span class=\"bwct31415\" \/><br \/>\n<\/span><\/p>\n<p>       Merck<br \/>Media:<br \/>Pamela Eisele, (267) 305-3558<br \/>Sarra S.        Herzog, (908) 740-1871<br \/>or<br \/>Investors:<br \/>Teri Loxam, (908)        740-1986<br \/>Michael DeCarbo, (908) 740-1807     <\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing authorization for two HIV-1 medicines: DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and PIFELTRO\u2122 (doravirine, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines. DELSTRIGO and PIFELTRO are currently under EMA review for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the non-nucleoside reverse transcriptase class, lamivudine or tenofovir. These two recommendations will now be reviewed by the European Commission for marketing authorization in the European Union. Marketing authorization<\/p>\n","protected":false},"template":"","meta":{"_acf_changed":false,"bdl_company_name":[],"bdl_item_external_link":[],"inpsyde_pem_expiration_date":[],"inpsyde_pem_expiration_action":[],"footnotes":""},"tags":[53,64,289],"class_list":["post-745664","news_item","type-news_item","status-publish","hentry","tag-corporate-news","tag-latest-news","tag-press-release"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.6 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Merck Receives Positive CHMP Opinion for DELSTRIGO\u2122 (doravirine\/lamivudine\/tenofovir disoproxil fumarate) and PIFELTRO\u2122 (doravirine) in the European Union for the Treatment of HIV-1 Infection - Merck.com<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Merck Receives Positive CHMP Opinion for DELSTRIGO\u2122 (doravirine\/lamivudine\/tenofovir disoproxil fumarate) and PIFELTRO\u2122 (doravirine) in the European Union for the Treatment of HIV-1 Infection - Merck.com\" \/>\n<meta property=\"og:description\" content=\"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing authorization for two HIV-1 medicines: DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and PIFELTRO\u2122 (doravirine, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines. DELSTRIGO and PIFELTRO are currently under EMA review for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the non-nucleoside reverse transcriptase class, lamivudine or tenofovir. These two recommendations will now be reviewed by the European Commission for marketing authorization in the European Union. Marketing authorization\" \/>\n<meta property=\"og:url\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/\" \/>\n<meta property=\"og:site_name\" content=\"Merck.com\" \/>\n<meta property=\"article:modified_time\" content=\"2025-11-07T06:27:02+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png\" \/>\n\t<meta property=\"og:image:width\" content=\"3056\" \/>\n\t<meta property=\"og:image:height\" content=\"1380\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data1\" content=\"9 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\\\/\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\\\/\",\"name\":\"Merck Receives Positive CHMP Opinion for DELSTRIGO\u2122 (doravirine\\\/lamivudine\\\/tenofovir disoproxil fumarate) and PIFELTRO\u2122 (doravirine) in the European Union for the Treatment of HIV-1 Infection - Merck.com\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\"},\"datePublished\":\"2018-09-20T15:30:00+00:00\",\"dateModified\":\"2025-11-07T06:27:02+00:00\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\\\/\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news\\\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"News\",\"item\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/news-archive\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Merck Receives Positive CHMP Opinion for DELSTRIGO\u2122 (doravirine\\\/lamivudine\\\/tenofovir disoproxil fumarate) and PIFELTRO\u2122 (doravirine) in the European Union for the Treatment of HIV-1 Infection\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/#website\",\"url\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/\",\"name\":\"Merck.com\",\"description\":\"Just another vip-msd.com site\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/vip2-msd.com\\\/merckcom-migrated\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Merck Receives Positive CHMP Opinion for DELSTRIGO\u2122 (doravirine\/lamivudine\/tenofovir disoproxil fumarate) and PIFELTRO\u2122 (doravirine) in the European Union for the Treatment of HIV-1 Infection - Merck.com","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/","og_locale":"en_US","og_type":"article","og_title":"Merck Receives Positive CHMP Opinion for DELSTRIGO\u2122 (doravirine\/lamivudine\/tenofovir disoproxil fumarate) and PIFELTRO\u2122 (doravirine) in the European Union for the Treatment of HIV-1 Infection - Merck.com","og_description":"Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending granting of marketing authorization for two HIV-1 medicines: DELSTRIGO\u2122, a once-daily fixed-dose combination tablet of doravirine (100 mg), lamivudine (3TC, 300 mg) and tenofovir disoproxil fumarate (TDF, 300 mg); and PIFELTRO\u2122 (doravirine, 100 mg), a new non-nucleoside reverse transcriptase inhibitor (NNRTI) to be administered in combination with other antiretroviral medicines. DELSTRIGO and PIFELTRO are currently under EMA review for the treatment of adults with HIV-1 infection without past or present evidence of resistance to the non-nucleoside reverse transcriptase class, lamivudine or tenofovir. These two recommendations will now be reviewed by the European Commission for marketing authorization in the European Union. Marketing authorization","og_url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/","og_site_name":"Merck.com","article_modified_time":"2025-11-07T06:27:02+00:00","og_image":[{"width":3056,"height":1380,"url":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-content\/uploads\/sites\/152\/2022\/03\/Merck.png","type":"image\/png"}],"twitter_card":"summary_large_image","twitter_misc":{"Est. reading time":"9 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/","name":"Merck Receives Positive CHMP Opinion for DELSTRIGO\u2122 (doravirine\/lamivudine\/tenofovir disoproxil fumarate) and PIFELTRO\u2122 (doravirine) in the European Union for the Treatment of HIV-1 Infection - Merck.com","isPartOf":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website"},"datePublished":"2018-09-20T15:30:00+00:00","dateModified":"2025-11-07T06:27:02+00:00","breadcrumb":{"@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/news\/merck-receives-positive-chmp-opinion-for-delstrigo-doravirine-lamivudine-tenofovir-disoproxil-fumarate-and-pifeltro-doravirine-in-the-european-union-for-the-treatment-of-hiv-1-in\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"News","item":"https:\/\/vip2-msd.com\/merckcom-migrated\/news-archive\/"},{"@type":"ListItem","position":2,"name":"Merck Receives Positive CHMP Opinion for DELSTRIGO\u2122 (doravirine\/lamivudine\/tenofovir disoproxil fumarate) and PIFELTRO\u2122 (doravirine) in the European Union for the Treatment of HIV-1 Infection"}]},{"@type":"WebSite","@id":"https:\/\/vip2-msd.com\/merckcom-migrated\/#website","url":"https:\/\/vip2-msd.com\/merckcom-migrated\/","name":"Merck.com","description":"Just another vip-msd.com site","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/vip2-msd.com\/merckcom-migrated\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"}]}},"acf":{"news_item_workflow_id":"49222d9d-c7fe-4c41-987e-d4744f8dce38","news_item_aria_label":"","media_files":null,"document_path":"","file":""},"_links":{"self":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745664","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item"}],"about":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/types\/news_item"}],"version-history":[{"count":1,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745664\/revisions"}],"predecessor-version":[{"id":3675012,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/news_item\/745664\/revisions\/3675012"}],"wp:attachment":[{"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/media?parent=745664"}],"wp:term":[{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/vip2-msd.com\/merckcom-migrated\/wp-json\/wp\/v2\/tags?post=745664"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}